$10 Billion Deal, page-1833

Its the company that reiterates the assay is a key element of demonstrating a key component of a cure strategy. Surely shareholders deserve an update. Directors did sell heaps of shares around 27c , imo they must have known some of the assay results by then.

Apr 6th 2018

"Taking this critical scientific step will extend timelines. The assay is technologically challenging and time consuming. However the analyses form a key element in Biotron’s strategy of demonstrating that the addition of BIT225 to cART has the ability to be a key component of an overall cure strategy for HIV-1."